IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
Key facts
- Who runs it
- Weizmann Institute of Science
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 11 May 2026
- Expected to end
- Nov 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Standard Low FODMAP dietary regimen
- personalized low FODMAP dietary regimen
- Record updated
- 15 October 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male and Female
- Age - 18-70
Who cannot take part
- Consumption of antibiotics 2 months prior to enrolment
- Consumption of probiotic supplements 2 weeks prior to enrolment
- Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study
- Unstable doses of medications in the past 2 months
- Type 1 or type 2 diabetes diagnosis
- Chronic disease - to the discretion of the study medical team
- Cancer and recent anticancer treatment
- Psychiatric disorders - to the discretion of the medical team
- History of gastrointestinal surgeries - to the discretion of the medical team
- Inflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team
- Immunosuppression
- Alcohol or substance abuse
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.
The 2 groups in the trial
- IBS - standard low FODMAPPlacebo, for comparison
individuals that are diagnosed with IBS according to Rome IV criteria Standard low FODMAP dietary regimen randomized re-introduction phase
Treatment: Standard Low FODMAP dietary regimen
- IBS - personalised low FODMAPTreatment being tested
individuals that are diagnosed with IBS according to Rome IV criteria FODMAP dietary regimen with personalized re-introduction phase
Treatment: personalized low FODMAP dietary regimen
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT05972317, who can take part
- Record updated
- 15 October 2026